FDA inspection
GlaxoSmithKline dba Human Genome Sciences Inc: FDA inspection ending Apr 26, 2013
FDA inspection 833256 · Voluntary Action Indicated (VAI) · Rockville, MD
Key facts
| Inspection ID | 833256 |
|---|---|
| Firm | GlaxoSmithKline dba Human Genome Sciences Inc |
| FEI number | 3003782237 |
| Address | 14200 Shady Grove Rd |
| City | Rockville |
| State | MD |
| ZIP | 20850-7464 |
| Fiscal year | 2013 |
| Inspection end date | Apr 26, 2013 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | New Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data